Journal of the American Academy of Dermatology
Volume 62, Issue 2 , Pages 205-217, February 2010

Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial

Presented at the 2008 Conference of the American Academy of Dermatology, San Antonio, TX, March 2008; the 2009 Conference of the American Academy of Dermatology, San Francisco, CA, March 2009; and the 2007 Annual Conference of the British Association of Dermatologists, Birmingham, UK, June 2007.

  • Annika Grant, RN

      Affiliations

    • Florida Academic Dermatology Centers, Miami, Florida
    • ,
  • Tayler Gonzalez, PharmD

      Affiliations

    • Centocor Inc, Horsham, Pennsylvania
    • ,
  • Michael O. Montgomery, MD

      Affiliations

    • Centocor Inc, Horsham, Pennsylvania
    • ,
  • Vanessa Cardenas

      Affiliations

    • Florida Academic Dermatology Centers, Miami, Florida
    • ,
  • Francisco A. Kerdel, MBBS

      Affiliations

    • Florida Academic Dermatology Centers, Miami, Florida
    • Corresponding Author InformationReprint requests: Francisco A. Kerdel, MBBS, Florida Academic Dermatology Centers, 1400 NW 12 St, Suite 4, Miami FL 33136.

Accepted 10 June 2009.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    •  Supported by Centocor Inc.

     Disclosure: Dr Kerdel, Ms Grant, and Ms Cardenas have received research support from Centocor Inc. Drs Gonzalez and Montgomery are employees of Centocor Inc.

    PII: S0190-9622(09)00782-8

    doi:10.1016/j.jaad.2009.06.050

    Journal of the American Academy of Dermatology
    Volume 62, Issue 2 , Pages 205-217, February 2010